

DAFTAR PUSTAKA

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med.*2020;382:727–33.
2. WHO(2021). Weekly operational update on COVID-19 - 30 August 2021. Available from : <https://www.who.int/publications/m/item/weekly-operational-update-on-covid-19---30-august-2021>. Diakses September 2021
3. WHO(2021). COVID-19 Weekly Situation Report SEA. World Heal Organ . 2020; Available from : <https://www.who.int/docs/default-source/searo/whe/coronavirus19/sear-weekly-reports/weekly-situation-report-week-37>. Diakses September 2021
4. Setiati S, Azwar MK. COVID-19 and Indonesia. *Acta Med Indones.* 2020;52:84-9.
5. Miller S. General Properties of Viruses. In: Carrol KC, Hobden JC, Miller S, Morse SA, Mietzner TA, Detrick B, editors. *Jawetz, Melnick & Adelberg's medical microbiology.* 27th ed. New York : Mcgraw-Hill Education;2015. p.397–419.
6. Maier HJ, Bickerton E, Britton P. Coronaviruses: Methods and protocols. *Coronaviruses Methods Protoc.* 2015;1282:1–282.
7. Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. *Methods Mol Biol.*2015;1282:1–23.
8. Cevik M, Kuppalli K, Kindrachuk J, Peiris M. Virology, transmission, and pathogenesis of SARS-CoV-2. *BMJ.*2020;371:1–7
9. Tay MZ, Poh CM, Renia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. *Nat Rev Immunol.*2020;20:363–74.
10. Wu R, Wang L, Kuo HCD, Shannar A, Peter R, Chou PJ, et al. An Update on Current Therapeutic Drugs Treating COVID-19. *Curr Pharmacol reports.*2020;6:56–70.
11. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids--new mechanisms for old drugs. *N Engl J Med.*2005;353:1711–23.
12. Ramamoorthy S, Cidlowski JA. Corticosteroids: Mechanisms of Action in Health and Disease. *Rheum Dis Clin North Am.*2016;42:15–31.
13. Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. *Allergy Clin Immunol.*2013;9:1–25.
14. Lai ST. Treatment of severe acute respiratory syndrome. *Eur J Clin Microbiol Infect Dis.* 2005;24:583–91.
15. Russell B, Moss C, Rigg A. Van Hemelrijck M. COVID-19 and treatment

with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting?. *Ecancermedicalsecience*.2020;14:1-3.

16. Patel VK, Shirbhate E, Patel P, Veerasamy R, Sharma PC, Rajak H. Corticosteroids for treatment of COVID-19: effect, evidence, expectation and extent. *Beni-Suef Univ J Basic Appl Sci*. 2021;10:1–13
17. Ye Z, Wang Y, Lozano LEC, Prasad M, Tangamornsuksan W, Rochweg B, et al. Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis. *Can Med Assoc J*.2020;192:756-67.
18. Urry LA. Viruses. In: Winickoff BN, Burner P, editors. *Campbell Biology*. 12th ed. San Fransisco: Pearson Benjamin Cummings; 2010. p. 398-419
19. Louten J. Virus Replication. In: Coulthurst F, editor. *Essential Human Virology*. 1st ed. London: Academic Press; 2016. p. 49–70.
20. Shah VK, Firmal P, Alam A, Ganguly D, Chattopadhyay S. Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past. *Front Immunol*.2020;11:1-17.
21. Santos I de A, Grosche VR, Bergamini FRG, Sabino-Silva R, Jardim ACG. Antivirals Against Coronaviruses: Candidate Drugs for SARS-CoV-2 Treatment?. *Front Microbiol*.2020;11:1-23.
22. Rabaan AA, Al-Ahmed SH, Haque S, Sah R, Tiwari R, Malik YS, et al. SARS-CoV-2, SARS-CoV, and MERS-CoV: A comparative overview. *Infez Med*. 2020;28:174–84.
23. Helmy YA, Fawzy M, Elasad A, Sobieh A, Kenney SP, Shehata AA. The COVID-19 Pandemic: A Comprehensive Review of Taxonomy, Genetics, Epidemiology, Diagnosis, Treatment, and Control. *J Clin Med*.2020;9:1-29.
24. Li H, Liu SM, Yu XH, Tang SL, Tang CK. Coronavirus disease 2019 (COVID-19): current status and future perspectives. *Int J Antimicrob Agents*.2020;55:1-29.
25. Astuti I, Ysrafil. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response. *Syndr Clin Res Rev*.2020;14:407–12.
26. Tsatsakis A, Calina D, Falzone L, Petrakis D, Mitrut R, Siokas V, et al. SARS-CoV-2 pathophysiology and its clinical implications: An integrative overview of the pharmacotherapeutic management of COVID-19. *Food Chem Toxicol*.2020;146:1-18.
27. V'kovski P, Kratzel A, Steiner S, Stalder H, Thiel V. Coronavirus biology and replication: implications for SARS-CoV-2. *Nat Rev Microbiol*.2021;19:155–70.
28. CDC(2021). Coronavirus (COVID-19) frequently asked questions. Available from : <https://www.cdc.gov/coronavirus/2019->

ncov/faq.html#Basics. Diakses September 2021.

29. Lovato A, de Filippis C, Marioni G. Upper airway symptoms in coronavirus disease 2019 (COVID-19). *American journal of otolaryngology*.2020;41:1-2.
30. Mason RJ. Pathogenesis of COVID-19 from a cell biology perspective. *Eur Respir J*.2020;55:1-3.
31. Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, et al. Inflammatory responses and inflammation-associated diseases in organs. *Oncotarget*.2018;9:7204–18.
32. García LF. Immune Response, Inflammation, and the Clinical Spectrum of COVID-19. *Front Immunol*.2020;11:1-13.
33. Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. *Cold Spring Harb Perspect Biol*.2009;1:1-11.
34. Liu T, Zhang L, Joo D, Sun SC. NF-κB signaling in inflammation. *Signal Transduct. Target Ther*.2017;2:1-9.
35. Boechat JL, Chora I, Morais A, Delgado L. The immune response to SARS-CoV-2 and COVID-19 immunopathology – Current perspectives. *Pulmonology*.2021;27:423–37.
36. Rabaan AA, Al-Ahmed SH, Muhammad J, Khan A, Sule AA, Tirupathi R, et al. Role of Inflammatory Cytokines in COVID-19 Patients: A Review on Molecular Mechanisms, Immune Functions, Immunopathology and Immunomodulatory Drugs to Counter Cytokine Storm. *Vaccines*.2021;9:1-23.
37. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. *JAMA*.2020;324:782–93.
38. Baj J, Juchnowicz HK, Teresiński G, Buszewicz G, Ciesielka M, Sitarz E, et al. COVID-19: Specific and Non-Specific Clinical Manifestations and Symptoms: The Current State of Knowledge. *J Clin Med*.2020;9:1-22.
39. Esakandari H, Nabi-Afjadi M, Fakkari-Afjadi J, Farahmandian N, Miresmaeili S-M, Bahreini E. A comprehensive review of COVID-19 characteristics. *Biol Proced Online*.2020;22:1-10.
40. WHO(2020). Coronavirus Q&A. Available from : <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/question-and-answers-hub/q-a-detail/coronavirus-disease-covid-19>. Diakses september 2020.
41. Zhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y. The epidemiology, diagnosis and treatment of COVID-19. *Int J Antimicrob Agents*.2020;55:1-13.
42. Long C, Xu H, Shen Q, Zhang X, Fan B, Wang C, et al. Diagnosis of the Coronavirus disease (COVID-19): rRT-PCR or CT? *Eur J*

- Radiol.2020;126:1-5.
43. Freeman WM, Walker SJ, Vrana KE. Quantitative RT-PCR: Pitfalls and Potential. *Biotechniques*.1999;26:112–25.
 44. Felsenstein S, Herbert JA, McNamara PS, Hedrich CM. COVID-19: Immunology and treatment options. *Clin Immunol*.2020;215:1-13.
 45. Hassanipour S. et al. The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials. *Sci Reports*.2021;11:1-11.
 46. Singh AK, Majumdar S, Singh R, Misra A. Role of corticosteroid in the management of COVID-19: A systemic review and a Clinician's perspective. *Diabetes Metab Syndr Clin Res Rev*.2020;14:971–8.
 47. Schimmer BP, Funder JW. Adrenocorticotrophic Hormone, Adrenal Steroids, and the Adrenal Cortex. In: Brunton LL, Dandan RH, Knollman BC. *Goodman & Gilman's The Pharmacological Basis of Therapeutics*. 13th Ed. New York:Mc Graw Hill Education;2018. p.845-61
 48. Samuel S, Nguyen T, Choi HA. Pharmacologic Characteristics of Corticosteroids. *J Neurocrit Care*.2017;10:53–9.
 49. Mescher AL. Endocrine Glands. In: Weitz M, Kearns B, editors. *Junqueira's Basic Histology: Text and Atlas*. 14th ed. New York: McGraw-Hill Education; 2016. p. 413–38.
 50. Williams DM. Clinical Pharmacology of Corticosteroids. *Respir Care*. 2018;63:655–70.
 51. Chrousos GP. Adrenocorticoids & Adrenocortical Antagonist. In: Katzung BG, Trevor AJ, editors. *Basic & clinical pharmacology*. 13th ed. New York: McGraw-Hill Medical;2012. p.680-95
 52. Demoly P, Chung KF. Pharmacology of corticosteroids. *Respir Med*.1998;92:385–94.
 53. Streeten DH. Corticosteroid therapy. I. Pharmacological properties and principles of corticosteroid use. *JAMA*. 1975 Jun;232(9):944–7.
 54. Schäcke H, Döcke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. *Pharmacol Ther*. 2002 Oct 1;96:23–43.
 55. Theoharides TC, Conti P. Dexamethasone for COVID-19? Not so fast. *J Biol Regul Homeost Agents*. 2020;34:1241–3.
 56. Corssmit EPM, Dekkers OM. Screening in adrenal tumors. *Curr Opin Oncol*. 2019;31:243–6.
 57. Polderman JAW, Farhang-Razi V, Dieren VS, Kranke P, DeVries JH, Hollmann MW, et al. Adverse side-effects of dexamethasone in surgical patients - an abridged Cochrane systematic review. *Anaesthesia*. 2019;74:929–39.

58. Cohen EM. Dexamethasone. *Anal Profiles Drug Subst Excipients*. 1973;2:163–97.
59. Langhoff E, Ladefoged J. Relative immunosuppressive potency of various corticosteroids measured in vitro. *Eur J Clin Pharmacol*. 1983;25:459–62.
60. Czock D, Keller F, Rasche FM, Häußler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. *Clin Pharmacokinet*. 2005;44:61–98.
61. Garrod O. The Pharmacology of Cortisone, Cortisol (Hydrocortisone) and their New Analogues. *Postgrad Med J*. 1958;34:300–9.
62. Puspita S. Evaluasi Mutu Fisik Sediaan Krim Hidrokortison Generik dan Generik Berlogo. *J Para Pemikir*. 2018;7:275–8.
63. Sterne JAC, Murthy S, Diaz J V., Slutsky AS, Villar J, Angus DC, et al. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. *JAMA*. 2020;324:1330–41.
64. Hydrocortisone | C21H30O5 - PubChem. Available from : <https://pubchem.ncbi.nlm.nih.gov/compound/Hydrocortisone>. Diakses Desember 2021.
65. Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC, et al. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients with Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. *JAMA - J Am Med Assoc*. 2020;324(13):1307–16.
66. Ranjbar K, Moghadami M, Mirahmadizadeh A, Fallahi MJ, Khaloo V, Shahriarirad R, et al. Correction to: Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial. *BMC Infect Dis*. 2021;21(1):1–8.
67. Munch MW, Myatra SN, Vijayaraghavan BKT, Saseedharan S, Benfield T, Wahlin RR, et al. Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive without Life Support in Adults with COVID-19 and Severe Hypoxemia: The COVID STEROID 2 Randomized Trial. *JAMA - J Am Med Assoc*. 2021;326(18):1807–17.
68. Pinzón MA, Ortiz S, Holguín H, Betancur JF, Arango DC, Laniado H, et al. Dexamethasone vs methylprednisolone high dose for Covid-19 pneumonia. *PLoS One*. 2021;16:1–13.
69. Granholm A, Munch MW, Myatra SN, Vijayaraghavan BKT, Cronhjort M, Wahlin RR, et al. Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial. *Intensive Care Med*. 2022;48(1):45–55

70. Bartoletti M, Marconi L, Scudeller L, Pancaldi L, Tedeschi S, Giannella M, et al. Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicentre study. *Clin Microbiol Infect.* 2021;27(1):105–11.
71. Corral-Gudino L, Bahamonde A, Arnaiz-Revillas F, Gómez-Barquero J, Abadía-Otero J, García-Ibarbia C, et al. Methylprednisolone in adults hospitalized with COVID-19 pneumonia : An open-label randomized trial (GLUCOCOVID). *Wien Klin Wochenschr.* 2021;133:303–11.
72. Wu C, Hou D, Du C, Cai Y, Zheng J, Xu J, et al. Corticosteroid therapy for coronavirus disease 2019-related acute respiratory distress syndrome: a cohort study with propensity score analysis. *Crit Care.* 2020;24(1):1–10.
73. Vidal-Cortés P, Río-Carbajo L Del, Olmo JN Del, Prol-Silva E, Tizón-Varela AI, Rodríguez-Vázquez A, et al. Covid-19 and acute respiratory distress syndrome. Impact of corticosteroid treatment and predictors of poor outcome. *Rev Esp Quimioter.* 2021;34(1):33–43.
74. Monedero P, Gea A, Castro P, Candela-Toha AM, Hernández-Sanz ML, Arruti E, et al. Early corticosteroids are associated with lower mortality in critically ill patients with COVID-19: a cohort study. *Crit Care.* 2021;25(1):1–13.
75. Ghanei M, Solaymani-Dodaran M, Qazvini A, Ghazale AH, Setarehdan SA, Saadat SH, et al. The efficacy of corticosteroids therapy in patients with moderate to severe SARS-CoV-2 infection: a multicenter, randomized, open-label trial. *Respir Res.* 2021;22(1):1–14.
76. Zha L, Li S, Pan L, Tefsen B, Li Y, French N, et al. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). *Med J Aust.* 2020;212(9):416–20.
77. Bahl A, Johnson S, Chen NW. Timing of corticosteroids impacts mortality in hospitalized COVID-19 patients. *Intern Emerg Med* [Internet]. 2021;16(6):1593–603.
78. Aggarwal A, Mittal A, Soneja M, Shankar SH, Naik S, Kodan P, et al. Role of systemic corticosteroids in preventing hypoxia among patients with mild COVID-19: An observational study. *Drug Discov Ther.* 2021;15(5):273–7.
79. Rodríguez-Molinero A, Pérez-López C, Gálvez-Barrón C, Miñarro A, Rodríguez Gullello EA, Collado Pérez I, et al. Association between high-dose steroid therapy, respiratory function, and time to discharge in patients with COVID-19: Cohort study. *Med Clínica.* 2021;156(1):7–12.
80. Chen H, Xie J, Su N, Wang J, Sun Q, Li S, et al. Corticosteroid Therapy Is Associated With Improved Outcome in Critically Ill Patients With COVID-19 With Hyperinflammatory Phenotype. *Chest.* 2021;159(5):1793–802.
81. Jahani M, Dokaneheifard S, Mansouri K. Hypoxia: A key feature of COVID-19 launching activation of HIF-1 and cytokine storm. *J Inflamm.* 2020;17(1):1–10.

82. Jha NK, Jeyaraman M, Rachamalla M, Ojha S, Dua K, Chellappan DK, et al. Current Understanding of Novel Coronavirus: Molecular Pathogenesis, Diagnosis, and Treatment Approaches. *Immuno* 2021;1:30-66
83. Kementerian Kesehatan RI(2020). Pedoman Pencegahan dan Pengendalian COVID-19. Available from: <https://covid19.kemkes.go.id/protokol-covid-19/kmk-no-hk-01-07-menkes-413-2020-ttg-pedoman-pencegahan-dan-pengendalian-covid-19>, Diakses April 2022.
84. Williams DM. Clinical Pharmacology of Corticosteroids. *Respir Care*. 2018;63:655–70.
85. Jiang B, Wei H. Oxygen therapy strategies and techniques to treat hypoxia in COVID-19 patients. *Eur Rev Med Pharmacol Sci*. 2020;24(19):10239–46.
86. Gibson PG, Qin L, Pua SH. COVID-19 acute respiratory distress syndrome (ARDS): clinical features and differences from typical pre-COVID-19 ARDS. *Med J Aust*. 2020;213:54–56.e1
87. Bertsimas D, Lukin G, Mingardi L, Nohadani O, Orfanoudaki A, et al. (2020) COVID-19 mortality risk assessment: An international multi-center study. *PLOS ONE* 15: 1–10
88. Ali N. Elevated level of C-reactive protein may be an early marker to predict risk for severity of COVID-19. *J Med Virol*. 2020;92:2409–11.

